Axsome Therapeutics (AXSM) Capital Leases (2024 - 2026)

Axsome Therapeutics has disclosed Capital Leases across 3 years of filings, most recently posting $5.8 million for Q1 2026.

• Capital Leases for Q1 2026 came in at $5.8 million, up 58.8% year-over-year; the trailing twelve-month figure through Mar 2026 was $5.8 million (up 58.8% YoY), and the FY2025 annual result was $4.2 million, up 42.92% from the prior year.
• Capital Leases came in at $5.8 million for Q1 2026 at Axsome Therapeutics, up from $4.2 million in the prior quarter.
• In the past five years, Capital Leases ranged from a high of $5.8 million in Q1 2026 to a low of $1.7 million in Q1 2024.
• The 3-year median for Capital Leases is $3.7 million (2025), against an average of $3.6 million.
• Peak annual rise in Capital Leases reached 116.85% in 2025, while the deepest fall reached 25.36% in 2025.
• Axsome Therapeutics' Capital Leases stood at $2.9 million in 2024, then jumped by 42.92% to $4.2 million in 2025, then jumped by 38.94% to $5.8 million in 2026.
• The last three Capital Leases figures came in at $5.8 million (Q1 2026), $4.2 million (Q4 2025), and $4.7 million (Q3 2025), per Business Quant data.